EP2170390
Mótefnablöndur með natalízýmab
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
13.6.2008EP published:
7.11.2018EP application number:
08771026.5
EP translation filed:
19.12.2018Grant published:
15.1.2019EPO information:
European Patent Register
Max expiry date:
12.6.2028Expiry date:
12.6.2026Next due date:
30.6.2026
Title:
NATALIZUMAB ANTIBODY FORMULATIONS
Timeline
Today
13.6.2008EP application
7.11.2018EP Publication
19.12.2018Translation submitted
15.1.2019Registration published
12.6.2026Expires
Owner
Name:
Biogen MA Inc.Address:
225 Binney Street, 02142, Cambridge, MA, US
Inventor
Name:
MALONEY, KevinAddress:
Nashua, NH, US
Agent
Name:
Orsnes PatentAddress:
Sentvedvej 23, DK
Priority
Number:
944076 PDate:
14.6.2007Country:
US
Classification
Categories:
A61K 39/395, C07K 16/28
Annual fees
Number
Paid
Expires
Payer
Number: 12
Paid: 19.6.2019
Expires: 12.6.2020
Payer: Guðjón Styrkársson, hrl.
Number: 13
Paid: 5.5.2020
Expires: 12.6.2021
Payer: Árnason Faktor ehf.
Number: 14
Paid: 11.5.2021
Expires: 12.6.2022
Payer: Árnason Faktor ehf.
Number: 15
Paid: 6.5.2022
Expires: 12.6.2023
Payer: Árnason Faktor ehf.
Number: 16
Paid: 24.5.2023
Expires: 12.6.2024
Payer: Árnason Faktor ehf.
Number: 17
Paid: 21.5.2024
Expires: 12.6.2025
Payer: Árnason Faktor ehf.
Number: 18
Paid: 4.6.2025
Expires: 12.6.2026
Payer: Árnason Faktor ehf.